Issue 27
press REVIEW Chanez P, de Blic J, Delacourt C et al. Rev Mal Respir 2006;23:607-18. Clinical and therapeutic aspects of mild asthma M ild asthma, which according to the GINA (Global Initiative for
Download articleIssue 27
FORUM Physician-patient cross view on allergies and desensitisation A wide-ranging study, carried out in France in the spring of 2006 with patients and doctors, has led to a better understanding of t
Issue 27
SCIENTIFIC MATTERS Molecular immunology of grass pollen allergens Grass (or Poaceae) pollens are one of the most important airborne allergen sources worldwide. The temperate pasture grass subfamily o
Issue 27
CLINICAL MATTERS Grass pollen desensitisation tablets: safety and tolerability A phase I study evaluated the safety and tolerance of four different desensitisation protocols of desensitisation using
Issue 27
ABOUT THE PATIENT Contribution of international studies to the epidemiology of respiratory allergies The results of the first stages of large international multi-centre studies conducted in the 1990s
Issue 27
Sublingual desensitisation is effective against allergic symptoms and recent data indicate that, as with subcutaneous desensitisation, it too has the ability to change the long-term natural history of
Issue 27
A new day is dawning for allergic patients. Although treatments for allergic rhinitis, conjunctivitis and asthma are well consolidated and without significant side effects, there are still a relative
Issue 27
A new day is dawning for allergic patients. Although treatments for allergic rhinitis, conjunctivitis and asthma are well consolidated and without significant side effects, there are still a relative
Issue 27
HIGHLIGHTS The EAACI 2007 Congress Göteborg (Sweden) 9-13 June 2007 This XXVIth congress of the EAACI (European Academy of Allergology and Clinical Immunology) was an excellent meeting, with a very
Issue 27
CLINICAL MATTERS Immunotherapy and allergic rhinitis: Clinical relevance of the magnitude of improvement observed in studies The magnitude of the clinical effect observed in trials is an essential el
Issue 27
ABOUT THE PATIENT Allergic patients and their treatment: From dissatisfaction to non-compliance, what is the solution? An interview with Professor Ralph Mösges, Otorhinolaryngologist and Allergologi
Issue 27
SCIENTIFIC MATTERS A murine model of sublingual immunotherapy A murine model of sublingual immunotherapy has been developed in order to evaluate the efficacy of formulations and adjuvants to incorpor
Issue 27
FORUM Venom immunotherapy in Slovenia Up to 4% of the population is allergic to Hymenoptera venoms and about 0,1% of the population suffers from severe anaphylaxis. Those patients are at risk of seve
Issue 27
press REVIEW Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P, Jarvis D; European Community Respiratory Health Survey I. Allergy 2007;62:301-9. Geographical variations of sensitisation to common
Issue 27
HIGHLIGHTS The EAACI 2007 Congress Göteborg (Sweden) 9-13 June 2007 This XXVIth congress of the EAACI (European Academy of Allergology and Clinical Immunology) was an excellent meeting, with a very
Issue 27
CLINICAL MATTERS Immunotherapy and allergic rhinitis: Clinical relevance of the magnitude of improvement observed in studies The magnitude of the clinical effect observed in trials is an essential el
Issue 27
ABOUT THE PATIENT Allergic patients and their treatment: From dissatisfaction to non-compliance, what is the solution? An interview with Professor Ralph Mösges, Otorhinolaryngologist and Allergologi
Issue 27
SCIENTIFIC MATTERS A murine model of sublingual immunotherapy A murine model of sublingual immunotherapy has been developed in order to evaluate the efficacy of formulations and adjuvants to incorpor
Issue 27
FORUM Venom immunotherapy in Slovenia Up to 4% of the population is allergic to Hymenoptera venoms and about 0,1% of the population suffers from severe anaphylaxis. Those patients are at risk of seve
Issue 27
press REVIEW Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P, Jarvis D; European Community Respiratory Health Survey I. Allergy 2007;62:301-9. Geographical variations of sensitisation to common
Issue 26
press REVIEW Chanez P, de Blic J, Delacourt C et al. Rev Mal Respir 2006;23:607-18. Clinical and therapeutic aspects of mild asthma M ild asthma, which according to the GINA (Global Initiative for
Issue 26
FORUM Physician-patient cross view on allergies and desensitisation A wide-ranging study, carried out in France in the spring of 2006 with patients and doctors, has led to a better understanding of t
Issue 26
SCIENTIFIC MATTERS Molecular immunology of grass pollen allergens Grass (or Poaceae) pollens are one of the most important airborne allergen sources worldwide. The temperate pasture grass subfamily o
Issue 26
CLINICAL MATTERS Grass pollen desensitisation tablets: safety and tolerability A phase I study evaluated the safety and tolerance of four different desensitisation protocols of desensitisation using
Issue 26
ABOUT THE PATIENT Contribution of international studies to the epidemiology of respiratory allergies The results of the first stages of large international multi-centre studies conducted in the 1990s
Issue 26
Sublingual desensitisation is effective against allergic symptoms and recent data indicate that, as with subcutaneous desensitisation, it too has the ability to change the long-term natural history of
Issue 25
Press review Venter C, Pereira B, Grundy J, Clayton CB, Arshad SH, Dean T. Pediatr Allergy Immunol 2006; 17: 356–63. Prevalence of food allergy in children his study of a population cohort of 6 yea
Issue 25
FORUM The place of SLIT in the treatment of allergic rhinitis New therapeutic perspectives in allergic rhinitis can, of course, be considered from the patient's point of view, but also from the point
Issue 25
HIGHLIGHTS Zoom on EAACI (Vienna, June 10-14 2006) This year the congress of the European Academy of Allergology and Clinical Immunology (EAACI) was placed under the sign of advances in research, as
Issue 25
Clinical MATTERS Sublingual desensitisation in paediatrics: more than 10 years' experience Sublingual immunotherapy (SLIT) is a therapeutic option conceivable as early as 5 years old for allergic rhi
Issue 25
About the patient Listening to patients and their families K nowing how to answer to patient's expectations and requests is an integral part of the treatment for asthma and allergies. The patient-d
Issue 25
Dear colleagues, It is not a secret anymore: allergic diseases start very early in life, in many cases already in infancy. It has also become clear during the last decade that although a significant p
Issue 24
Scientific report Which markers can be used to evaluate the efficacy of specific immunotherapy? Research into biological markers of efficacy in desensitization has aroused the interest of many scient
Issue 24
Questions-answers The main stages of SLIT: from concept to practice Prof. F Marcucci (Perugia, Italy) reports on the main stages of SLIT (from concept to practice) and his experience in using it over
Issue 24
Press review D Aronsson, E Tufvesson and L Bjermer. Clin Exp Allergy 2005; 35: 1457-61. Dyspnea and exhaled fraction levels of nitric oxide: difference in allergic rhinitis whether or not associated
Issue 24
Forum High-dose Staloral with ultra-rush titration: confirmation of its efficacy and good safety profile High-dose immunotherapy achieved by ultrarush titration (rapid dose increments at the start of
Issue 24
Focusing on the patient From compliance to therapeutic adherence… The management of chronic diseases is not conducive to discussing recovery with sufferers, wherein lies the patient's difficulty in
Issue 24
Content ABOUT THE PATIENT 4 From compliance to therapeutic adherence… Interview with Pr D Vervloet (Marseille, France) SCIENTIFIC REPORT 7 Which markers can be used to evaluate the efficacy of spec
Issue 23
@PVRagVSVP£`HggRef SLIT mechanisms of action The evolution of SLIT The safety and efficacy of modern allergen specific immunotherapy (SIT) is widely recognised. New knowledge is emerging about its
Issue 23
A670$"3£)0()30()A@ «Food may (or may not) contain nut traces» The food industry is quite rightly persistently subject to public and institutional scrutiny. The European Union is currently funding
Issue 23
79&@@£9&C0&D Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Bowen T, Greenbaum J, Charbonneau Y, et al. Ann Allergy Asthma Immunol 2004; 93: 425-430. Starting S
Issue 23
QVfPhffVba£cbVagf INTERVIEW… Westmead Hospital, Sydney, New South Wales (Australia). Expressions. Is the use of specific immunotherapy (SIT) widespread in Australia or restricted to a few speciali
Issue 23
$3050$"3£VffhRf The cost of allergic rhinitis and asthma Too often under diagnosed, incorrectly treated and poorly supervised, allergy constantly progresses. Allergic rhinitis and asthma are promine
Issue 23
PHfR£UVfgber A case for double sublingual immunotherapy? Juliette, a 12-year-old girl from Champagne (France), with an unremarkable medical history, has had persistent rhinitis for four years. Clini
Issue 23
Welcome to the summer issue of Expressions. In addition to the regular contents, this issue contains two main features concerning the pharmaco-economics of specific allergen immunotherapy and the late
Issue 22
TOPICAL HIGHLIGHTS Vespid Allergens Reassessed Since the last survey of European wasps was carried out over thirty years ago, members of the allergy department in Elche General Hospital in Spain have
Issue 22
Scientific matters Tablet technology for easier immunotherapy The mouth is a site rich in dendritic cells that seem to have a key role in turning the switch from IgE to IgG production. Sublingual imm
Issue 22
regulatory dossier Quality rules in Europe and France Regulations concerning allergens used in immunotherapy have changed a great deal in France over recent months. INTERVIEW… with Mr Cheron Resp
Issue 22
PRESS REVIEW Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Bolhaar STHP, Tiemsen MM, Zuidmeer L et al. Clinical and Ex
Issue 22
CLINICAL issues High doses protocols for SLIT Fig.1 RAPID INITIATION PROTOCOL Following the development of standardised extracts for sublingual administration, it has been shown that high doses can
Issue 22
"#$%#&!'(!)*+,,#-%$.(&/0+(!10(2+3+4#( N° 22 - Février 2005 Protocoles à fortes doses de l'ITS sublinguale Interview du Pr H.F. Merk, Université Clinique RWTH de Aachen, (Allemagne). DOSSIER SCIE
Issue 22
Together with some interesting news and reviews, this issue of Expressions has an emphasis on new rapid initiation protocols and the potential for tablet technology. Immunotherapy depends upon exposin
Issue 21
@PVRagVSVP£`HggRef The allergy march explained The prevalence of allergic disease increased considerably over the last 40 years; one study showed that the percentage of French students with allergy
Issue 21
eRThYHgber£QbffVRe A new regulatory setting for NPP (Named Patient Product ) NEW DECREE FOR NPP* Following legislation passed on June 7th 1960, laboratories in France received authorisation to manuf
Issue 21
79&@@£9&C0&D In vitro allergen-induced RNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. Laakso
Issue 21
QVfPhffVba£cbVagf INTERVIEW… with Pr J. E. Rosado Pinto, Head of the Department of Allergology and Clinical Immunology. Hospital d'Estefânia, Lisbon (Portugal). Expressions. The Sixth Internatio
Issue 21
$3050$"3£VffhRf SLIT vs SCIT - The first placebo controlled trial Sublingual immunotherapy (SLIT) has been investigated for at least fifteen years. Many controlled studies have been conducted and mo
Issue 21
This issue of “Expressions” contains the findings of a 3-year study that has been described as representing a “cornerstone”,(1) being the first double-dummy placebo-controlled comparison of su
Issue 20
Expressions 6, RUE A. DE TOCQUEVILLE 92160 ANTONY – FRANCE Publications director: Stallergenes S.A. Steering Committee: Dr Emilio Alvarez-Cuesta (Spain), Pr Jean Bousquet (France), Pr Giorgio Walter
Issue 19
- 7216 - 09/03 Allergen Vaccines Worldwide Allergy essential cure www.stallergenes.com 6, rue Alexis de Tocqueville - 92183 Antony Cedex - France - Tél. : 33 1 55 59 21 00 - Fax : 33 1 55 59 20 02
Issue 18
Expressions 6, RUE A. DE TOCQUEVILLE 92183 ANTONY CEDEX Publications Director: Stallergènes SA Steering Committee: Dr Emilio Alvarez-Cuesta (Spain), Pr Jean Bousquet (France), Pr Giorgio Walter Canon
Issue 17
PRESS REVIEW PA Wachholz, K Nouri-Aria, DR Wilson, S Walker, A Verhoef, SJ Till, SR Durham. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1 /
Issue 16
Expressions 6, RUE A. DE TOCQUEVILLE 92183 ANTONY CEDEX Together, let's reach our goal. For a world Publications Director: Stallergènes SA Steering Committee: Dr Emilio Alvarez-Cuesta (Spain), Pr J
Issue 15
Expressions 6, RUE A. DE TOCQUEVILLE 92183 ANTONY CEDEX Together, let's reach our goal. For a world Publications Director: Stallergènes SA Steering Committee: Dr Emilio Alvarez-Cuesta (Spain), Pr J
